Authors

Sigrid Eckardt, PhD
Latest Article

Combining Oncolytic Immunotherapy With Checkpoint Inhibitors Could Affect Cure

Ongoing clinical trials are evaluating a new immunotherapeutic approach for the treatment of malignant melanoma–the combination of an oncolytic virus with checkpoint inhibition.

Sigurdis Haraldsdottir, MD
Sikander Ailawadhi, MD
Latest Article

Redefining Multiple Myeloma Diagnosis and Management

This article reviews some of the concepts surrounding the diagnosis of multiple myeloma are still evolving, and are thus shaping how we see and manage multiple myeloma - hopefully moving slowly but surely toward its elusive cure.

Silas Inman
Latest Article

ALINA 4-Year Update: Adjuvant Alectinib DFS Robust in ALK+ NSCLC

Alectinib shows remarkable 4-year survival rates in early-stage ALK-positive lung cancer, outperforming chemotherapy in disease-free survival and CNS recurrence.

Soumit Pendharkar, MHA, FACHE
Latest Article

Scheduling Tool Improves Infusion Center Efficiency

Coordinating appointments between the physician office suite and infusion center improved dramatically with the use of a scheduling optimization tool at the Cowell Family Cancer Center in Traverse City, Michigan. Specifically, the investigators observed a 6% reduction in median office-visit time and a 43% reduction in patient wait time in the infusion chair before infusion began.

Sramila Aithal, MD
Stacy D. Keppler, Pharm D, BCPS
Staff Writer
Latest Article

FDA Approves Second-Line Axi-Cel for Adults With LBCL

The FDA has granted approval to axicabtagene ciloleucel for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy, according to an announcement from the FDA.

Stanton R. Mehr
Latest Article

Sequester Forcing Chemo Treatments Into Hospitals Costing Taxpayers More

The federal sequester trims Medicare payments for cancer patients receiving chemotherapy in doctors’ offices in an effort to save the government money. Instead, it will end up costing more in the long run, according to the president of the American Society of Clinical Oncology.

Stella Morrison
Latest Article

KIT Mutations Provide Accurate Prediction of Outcome in GIST Diagnosis

Physicians may be able to use KIT mutations to help predict the progression of gastrointestinal stromal tumors (GISTs), according to a new meta-analysis published in Nature Scientific Reports.

Stephanie McClain, PharmD
Latest Article

Chronic Lymphocytic Leukemia: 2013 Update

Clinical study results presented at the 2013 American Society of Clinical Oncology Annual Meeting may offer new hope for patients with chronic lymphocytic leukemia.

Stephanie Mellon-Reppen, NP
Steve Carrell
Latest Article

Carcinoid Syndrome Symptoms May Improve With Telotristat Etiprate

A novel serotonin synthesis inhibitor, telotristat etiprate, helped reduce daily bowel movements for patients with carcinoid syndrome no longer responding to standard-of-care treatments, an encouraging sign for an emerging class of drugs.

Steven A. Toms, MD
Latest Article

NovoTTF and Temozolomide for Glioblastoma

Steven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses the combination of the Novo Tumor Treating Fields (NovoTTF) system and temozolomide for patients with glioblastoma.

Steven Eric Finkelstein, MD, FACRO
Latest Article

Radiation Therapy, Chemotherapy, Targeted Therapy, and Possibly Immunotherapy in Localized Sarcoma

Researchers offer a review of the role of adjuvant or neoadjuvant chemotherapy, targeted therapy, and immunotherapy in localized soft tissue sarcoma. 

Steven Finkelstein, MD
Steven I. Robinson, MBBS
Latest Article

Soft Tissue Sarcomas: Emerging and Novel Concepts

Soft tissue sarcomas are a rare and challenging group of malignancies of mesenchymal origin that have historically been treated with similar approaches.

Steven I. Sherman, MD
Latest Article

The Relationship Between Thyroid-Stimulating Hormone Levels and Outcomes From SELECT

Steven I. Sherman, MD, discusses the relationship between thyroid-stimulating hormone levels and outcomes from the phase III SELECT trial.

Steven P. Treon, MD, PhD
Sukumar Nagendran, MD
Latest Article

The Utility of the BRCAvantage Test

Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.

Sung W. Choi, MD
Sungyub Lew, MD
Latest Article

Hypertension Risk Among Cancer Patients Treated With Sunitinib: A Meta-analysis and Systematic Review

Sunitinib treatment is associated with a significantly increased risk of all-grade and high-grade hypertension.

Surabhi Dangi-Garimella, PhD
Latest Article

Value-Based Agreements Take Center Stage at COA Summit

Pressure on regulators to reduce healthcare costs could be a response to the estimated $1 trillion in US expenditures from poor care coordination, administrative burdens, and fraud, said Jeff Mortier, partner at Farragut Partners, during the Community Oncology Alliance Payer Exchange Summit.

Surabhi Dangi-Garimella, PhD, AJMC Writer
Latest Article

Panelists Highlight Ways to Ease Transition to Value-Based Care

In a panel discussion this morning during the Association of Community Cancer Center (ACCC)’s 44th Annual Meeting & Cancer Center Business Summit, experts stressed the importance of integrating team-based care to break silos and allow a continued care transition as the move continues toward value-based care.

Susan F. Slovin, MD, PhD
Suzanne Morris, DVM
Latest Article

Progress in Prostate Cancer Care: Highlights From a Decade of Innovation

Targeted Therapies in Oncology asked some experts in prostate cancer diagnostics and therapeutics for their thoughts on the milestone improvements in treating patients with prostate cancer over the past decade.

Tara Petersen
Latest Article

Amorphous Treatment Paradigm in Melanoma Provides Countless Options

As new information regarding the efficacy of targeted and immunotherapeutic approaches emerge, the standard of care for patients with melanoma becomes slightly more altered.

Targeted Oncology Staff Writer
Latest Article

Tailoring Regimens for Different Age Groups With Multiple Myeloma

During a Case-Based Roundtable® event, Andrew Yee, MD, discussed myeloma treatment strategies for different age groups, focusing on personalized regimens and the pros and cons of CAR T-cell therapy and bispecific antibodies in the second article of a 2-part series.

Targeted Therapies in Oncology Staff
Latest Article

Roundtable Discussion: Dietrich and Santos Look at Targeted Treatments for Patients With NSCLC

A 72-year-old White man presented with chest pain, cough, and dyspnea. He had a medical history of type 1 diabetes that was adequately controlled, and was a former smoker.

Targeted Therapies in Oncology Staff Writer
Latest Article

GRIFFIN Follow-Up Shows Promising Responses With Daratumumab plus VRD

Updated results of the GRIFFIN trial revealed that the addition of daratumumab to a standard-of-care regimen used in the treatment of newly diagnosed multiple myeloma met the trials primary end point of higher rates of stringent complete response in patients who are eligible for transplant.